Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06216002

Incidence of Residual Neuromuscular Blockade in Fraility in OncoGynae Surgery

Incidence of Residual Neuromuscular Blockade in Patients With Frailty Undergoing Gynecologic Cancer Surgery

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
622 (estimated)
Sponsor
Mahidol University · Academic / Other
Sex
Female
Age
18 Years
Healthy volunteers
Not accepted

Summary

Frailty among patients undergoing surgery is strongly associated with an elevated risk of adverse perioperative outcomes, heightened incidence of postoperative complications, increased mortality rates, and prolonged hospital length of stay. Our focus centers on investigating the frailty index in the context of complications experienced by patients undergoing oncologic gynecology surgery. The principal objective of this research is to elucidate the extent to which residual neuromuscular blocking agents are linked to frailty.

Detailed description

Among patients undergoing oncologic gynecological procedures, such as those for vulvar cancer, endometrial cancer, and ovarian cancer, the incidence of frailty has been observed to range from 14% to 45%. Frailty directly influences the metabolism of anesthetic agents and intraoperative management. Furthermore, the prevalence of residual neuromuscular blocking agents following surgery can be as high as 26% to 53%. No prior research has investigated the correlation between residual muscle relaxants and frailty in gynecologic oncology patients. This study is designed to assess the prevalence of residual muscle relaxants in these patients with frailty. Additionally, data on the incidence of frailty and its impact on postoperative outcomes and prognosis in patients undergoing gynecologic oncology surgery will be collected and reported.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTTrain of four nerve stimulatorPatient receive nerve stimulation by TOF-scan equipment at recovery room after surgery.

Timeline

Start date
2024-01-02
Primary completion
2025-12-31
Completion
2025-12-31
First posted
2024-01-22
Last updated
2025-05-08

Locations

1 site across 1 country: Thailand

Source: ClinicalTrials.gov record NCT06216002. Inclusion in this directory is not an endorsement.